Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its patented therapeutic candidate Lucid-MS for the treatment of multiple sclerosis (MS), a chronic autoimmune and neurodegenerative disease that affects more than 2.8 million people worldwide, including approximately 1 million in the United States. The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
Multiple sclerosis remains one of the most challenging neurological diseases because of its progressive nature, unpredictable course and lack of a cure. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Quantum BioPharma’s Lucid-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity, which affects the loss of mobility or control of a person’s body.
In April 2026, the company reached a significant milestone with the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for Lucid-MS. This step moves the therapy closer to clinical trials in patients with MS. The company's efforts target demyelination and provide neuroprotection to address loss of mobility and function, potentially offering a new approach for patients who continue to experience worsening disability despite available immune-modulating therapies.
For more information, visit the company's newsroom at https://ibn.fm/QNTM. About BioMedWire: BioMedWire is a specialized communications platform focusing on the latest developments in the biotechnology, biomedical sciences and life sciences sectors. It is part of the Dynamic Brand Portfolio @IBN. For more information, visit https://www.BioMedWire.com. See the full terms of use and disclaimers on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.
